At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 28 enrolled
Drug / intervention
Duaveedrug
Likely dose
Duavee 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Study of the Effect of Duavee® on Benign Breast Tissue Proliferation in Peri or Post-menopausal Women at Moderate Risk for Development of Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Duavee for Breast Cancer. Completed, enrolled 28 participants across 2 sites.
Detailed Summary
The purpose of this study is to learn whether daily use of Duavee® is accepted and tolerated by peri- and post-menopausal women at moderate risk for development of breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsPfizer
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 2016
Enrollment StartMay 2016
Primary CompletionJan 2019
Study CompletionJun 2019
TodayJul 2026
First PostedApr 6, 2016
Enrollment StartMay 1, 2016
Primary CompletionJan 1, 2019
Study CompletionJun 1, 2019
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 10.2 years ago
Interventions
Duaveedrug
Once daily tablet of Duavee (Bazedoxifene (20 mg) plus conjugated estrogen (0.45 mg))